Bioequivalence study of Mirabegron 50 mg Extended-Release tablets manufactured by Faran Shimi Pharmaceutical Company vs. Betmiga ® tablets manufactured by Astellas Company in healthy volunteers

Authors
Category Primary study
Registry of TrialsIranian Registry of Clinical Trials
Year 2026
This article has no abstract
Epistemonikos ID: d0b62a5ee675e93612839dbbdb17c2201a4f5a0c
First added on: Oct 30, 2026